ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,920, issued on Nov. 25, was assigned to Ottimo Pharma Ltd. (Sandwich, Great Britain).
"PD1 and VEGFR2 dual-binding agents" was invented by William James Jonathan Finlay (Glasglow, Great Britain).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are antibody molecules that bind specifically to Programmed cell death 1 (PD1) and Vascular endothelial growth factor receptor 2 (VEGFR2), related nucleic acid molecules, vectors and host cells. Also provided herein are medical uses of such antibody molecules."
The patent was filed on Feb. 18, 2025, under Application No. 19/056,312.
*For further information, including images, charts and tables, ...